About PharmaJet

PharmaJet is a commercial stage MedTech Company with US and International distribution.

We work side by side with our partners to enable greater access to life improving pharmaceuticals

PharmaJet’s Needle-free Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. They are also safe, fast, and easy-to-use.

The PharmaJet Tropis® device for intradermal injections received authorization to apply the CE Mark in May 2016. An FDA Master File was established in August of 2017 as a precursor to 510(k) and Tropis received WHO Pre-Qualification (PQS) in June of 2018.

The innovative PharmaJet Stratis® Needle-Free Injector has U.S. FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines intramuscularly or subcutaneously. In August 2014, the PharmaJet Stratis Needle-free Injector was approved for delivery of an influenza vaccine to deliver needle-free flu shots.

The PharmaJet Team

Chris Cappello

President and Chief Executive Officer

Mr. Cappello was appointed Chief Operating Officer in 2018, and President and Chief Executive Officer in 2020. In this position, he is responsible for running all facets of the business. Chris has over 15 years of direct management experience in medical device development and sales, and has spent his career managing the successful design, development, clearance and launch of both reusable and high volume disposable medical devices. Prior to joining PharmaJet, he drove the development of disruptive medical device technologies at companies such as AlloSource and Applied Medical. Chris has a Bachelor of Science degree in Mechanical Engineering from Colorado State University and his Project Management Professional certification.

Jeffrey A. Jordan

Chief Financial Officer

Mr. Jordan has more than 25 years of experience in corporate finance. In his previous role, he directed the global finance functions for the Laboratory Products Group of Thermo Fisher Scientific, supporting $1.9B in annual revenue and 10,000 employees. Jeff has worked in several industries including life science tools, telecommunications and industrial chemicals. He has extensive experience in strategic planning, forecasting, significant capital investments, acquisitions and integration activities. Jeff has a Bachelor of Science degree in Mechanical Engineering from the United States Military Academy at West Point and an MBA from the University of Maryland.

Dan Mallon

Senior Vice President, Corporate Development

Mr. Mallon has 25 years of corporate development experience in the biopharmaceutical and medical device industries, where he has successfully identified market opportunities and stimulated product/business growth. He brings specific expertise in corporate strategy and development, alliance management, product marketing and government contracting. Prior to joining PharmaJet, Dan served in business development leadership positions at Ellume USA, RRD International and Emergent BioSolutions. He holds a Bachelor of Arts degree in Zoology from Miami University, and an MBA in Finance from the University of Maryland.

Paul LaBarre

Vice President, Global Business Development

Mr. LaBarre has 25 years of Medical Technology experience across the innovation value chain including regulatory, strategy, research, product development, and market analysis. He has held key business development roles at prominent healthcare organizations including UNICEF and PATH, as well as other health innovation organizations. Most recently he was Senior Vice President, Access and Innovation for SightLife, the world’s leading eye bank. Paul holds a Bachelor of Science degree in Mechanical Engineering from Northwestern University, a Master of Medical Engineering from the University of Washington, and an MBA from Mount Vernon Nazarene University.

Nathalie Landry

Chief Scientific Officer

Ms. Landry has over 30 years of experience in the successful development of a new technology platform as well as innovative vaccines and pharmaceuticals from proof-of-concept to late-stage clinical trials and regulatory approval. Prior to joining PharmaJet, she was Executive Vice President, Scientific and Medical Affairs at Medicago, an international leader in plant-based technology producing vaccines and therapeutics, where she led all R&D activities, analytical and process development, preclinical and clinical development, medical affairs, and pharmacovigilance activities. She has published over 25 articles in major international scientific journals, two book chapters and is co-inventor on 8 patent families. Nathalie holds a Master of Microbiology-Immunology and an MBA from the Université Laval.

Troy Chapman

Vice President, Operations

Mr. Chapman has more than 30 years of experience in the medical device industry across the fields of electrophysiology, electrosurgery, embolic coils and radioactive pharmaceuticals. Prior to joining PharmaJet he held engineering and leadership positions at Cardinal Health, ConMed and Covidien where he was responsible for research, development, and manufacturing. Troy has a Bachelor of Science degree in Mechanical Engineering from Purdue University.

Gordon Clancy

Chairman

Mr. Clancy has served on the Board since 2020 and was elected Chairman in 2024. He is a private investor, and a former Managing Partner of Citigroup Venture Capital International, a global private equity fund that invested primarily in emerging markets in a wide variety of industries, including pharmaceuticals and medical equipment. Prior to his involvement in private equity, Gordon worked in various roles in the Citigroup global capital markets and trading businesses. He holds a BA in Commerce and Economics and an MBA from the Rotman School of Management, both from the University of Toronto.

Al Stephan

Vice-Chairman

Mr. Stephan is a serial entrepreneur and investor, including early skunk-work developments on behalf of some of the largest and most respected global technology companies. Several of the companies he has incubated are focused on health, including flow cytometry, microfluidics for integrated laboratory testing for infectious disease, cancer, and respiratory disease using nucleic acid testing and blood analysis, multispectral imaging of cells, mass spectrometry, and medical devices affecting chronic pain. Al holds a BS in Mechanical Engineering from the University of Washington.

John “Spike” Buckley

Mr. Buckley is a commercial real estate developer with investments spanning the US and Canada, focused on enabling and impactful technology. He is an active angel investor in a variety of businesses and spends a significant amount of time on global initiatives focused on addressing the environment, climate change and promoting fair democracy. Spike is also an active board participant for several foundations. He holds a BA in Economics from the University of Colorado.

Heather Callender-Potters

Executive Vice President & Secretary

Ms. Callender-Potters is one of the co-founders of PharmaJet and has been active in the development and management of the Company since its formation. She has more than 25 years of private equity fund management and international investment experience across multiple jurisdictions, managing individual investments and financial investment consortiums (ING Barings, Enterprise Investors). Heather holds a BA in International Management from Claremont McKenna College and an MBA from the Wharton School, at the University of Pennsylvania.

Chris Cappello

President, and Chief Executive Officer

Mr. Cappello was appointed Chief Operating Officer in 2018, and President and Chief Executive Officer in 2020. In this position, he is responsible for running all facets of the business. Chris has more than 15 years of direct management experience in medical device development and sales, and has spent his career managing the successful design, development, regulatory clearance, and launch of both reusable and high volume disposable medical devices. Previously, he drove the development of disruptive medical device technologies at companies such as AlloSource and Applied Medical. Chris has a BS degree in Mechanical Engineering from Colorado State University and his Project Management Professional Certification.

Mark Jacobson

Mr. Jacobson’s career has been focused on private equity fund management, with experience across healthcare, drug manufacturing, fast moving consumer goods and a variety of infrastructure and technology businesses. He founded Ethemba Capital, a private equity fund which has deployed $500m+ into companies with operations across multiple emerging markets. Previously, he was with Citigroup Venture Capital International where he focused on emerging markets including the Middle East, Africa, and Central and Eastern European and CIS countries. Mark is a Chartered Accountant (South Africa) and holds a B Com in Investment Management and an M Com in Finance from the University of the Witwatersrand.

Marie Mazur, PharmD

Ms. Mazur has been on the Board since 2020, serving as chair in 2023, and is an adviser on special Company initiatives. She is a global business executive with 30+ years of pharmaceutical and vaccine industry experience, including Sanofi, 3M, GSK, and CSL Seqirus. Marie also serves on the Strategic Advisory Group of the Partnership for Influenza Vaccine Introduction (PIVI), a program from the Task Force for Global Health in partnership with the US Centers for Disease Control and Prevention. She holds a doctorate in Pharmacy and masters’ degree in Regulatory Affairs from Paris (France) University, and an International Executive Degree in Business Administration (IEP) from INSEAD Business School.

Sunil Nair

Mr. Nair is a global Private Equity/Venture Capital investor who has led/co-led over 40 transactions investing equity of over $2 billion in buyouts, expansion capital, privatizations, restructurings, and industry consolidations. Sunil’s global transactional expertise spans multiple sectors – pharmaceuticals, retail, transportation, telecommunications, real estate, banking, food/beverages, logistics, and multiple geographies – India, UK, Southeast Asia, Turkey, Poland, South Africa, and Egypt, among others. Previously he was Founding Partner, Managing Partner/Director of Citi Venture Capital International (“CVCI”) and also worked at McKinsey & Company. Sunil holds an MBA from Yale University.

Markus Pedriks

Mr. Pedriks is an active investor and entrepreneur, including Managing Partner of Baring Communications Equity (private equity closed end fund covering the Central and Eastern Europe and CIS regions). Skilled in operational leadership, sales and marketing, his areas of focus have primarily been in Europe and North America, in health, media, telecommunications, entertainment, and real estate. Markus holds a BA in Economics from McGill University, and an MBA from IMD, Lausanne, and is actively completing his PhD in Conflict Management from the University of Maimi.

Praful Shah, PhD

Dr. Shah is an international angel investor, with expertise in research and drug development, focused on minority-led and medical device companies. Previously he held leadership roles with Marion Labs and Myogen (acquired by Gilead), where he led product development for a pulmonary arterial hypertension drug. Praful began his career in medicinal chemistry at Pfizer Central Research, focused on synthesis of new peptide drugs. He has been a member of several boards, including the Alliance for Collective Action, the Rockies Venture Club, Investors Circle, and the Colorado Office of Economic Development & International Trade. Praful holds a BS in chemistry from Pace University, and a PhD in Pharmaceutical Chemistry from the University of Kansas.

Robert Wardrop, MSc, PhD

Dr. Wardrop is a Management Practice Professor of Finance at the University of Cambridge Judge Business School and the Director and Co-founder of the Cambridge Centre for Alternative Finance. He has 30 years of experience in starting, advising, and investing in small and medium sized companies in North America, Europe, and Asia. Previously Robert was Managing Director at Anschutz Investment Company, where he was responsible for a portfolio of European corporate debt and equity investments. He holds a BCom from Queen’s University, an MBA from the University of Chicago Booth School of Business, an MSc from the London School of Economics, and a PhD from the University of Cambridge.

Meet the subject matter experts that will assist the company to demonstrate how our delivery technology improves the performance of vaccines and therapeutics.

Infectious Diseases SAB
Cornelia Dekker, M.D.

Professor of Pediatrics (Infectious Diseases), Emerita, Stanford University School of Medicine

  • Former Vice President, Clinical Research and Medical Affairs, Chiron Vaccines
  • Former Medical Director, Stanford-LPCH Vaccine Program
James Merson, Ph.D.

Chief Virology Officer, Stealth Oncology Company

  • Former SVP and CSO, Vaccine Immunotherapeutics Research Unit, Pfizer
  • Former Global Therapeutic Area Head, Infectious Diseases, Janssen
Jonathan Nguyen-Van-Tam

Independent consultant

  • Public health trained physician and former Medical Director, Sanofi Pasteur MSD
  • Former Clinical Advisor – UK Covid -19 Vaccines Task Force
  • Former Deputy Chief Medical Officer, UK Government
Bali Pulendran, Ph.D.

Co-Director, Institute for Immunity, Transplantation and Infection, Stanford University, and Violetta L. Horton Professor of Pathology, and of Microbiology and Immunology

  • World renowned immunologist, and a pioneer of System Biology Approaches to predict the efficacy of vaccines, and decipher new correlates of protection against infectious diseases
  • Author/co-author of 260+ publications
Brian Ward, MDCM

Professor of Infectious Diseases/Microbiology, McGill University

  • Former Medical Officer, Medicago Inc.
  • Director of the McGill Vaccine Study Center
  • 30+ years of translational research at McGill University
Oncology SAB
Michael Gibson, M.D., Ph.D., FACP

Director, Translational Research for Esophago-Gastric Cancer (EGC) at the Vanderbilt-Ingram Cancer Center (VICC)

  • Associate Professor of Medicine at the Vanderbilt University Medical Center
  • Osler Medical Residency and Medical Oncology Fellowship, Johns Hopkins Hospital and PhD, Clinical Investigation (Johns Hopkins University Bloomberg School of Public Health)
Stephanie Mazzei, MSc

Founder and Director, OncoLogic Inc.

  • Global Oncology Strategy Advisor
  • Serial Entrepreneur and Board Leader
  • Former Change Agenda Leader, Global Oncology Business Unit, Eli Lilly and Company
Douglas McNeel, M.D., Ph.D.

Professor of Medicine, Director, Solid Tumor Immunology Research, Co-Director, University of Wisconsin Prostate SPORE, UW Carbone Cancer Center

  • Genitourinary medical oncologist with expertise in prostate cancer
  • Laboratory and clinical translational research focus on anti-tumor vaccines
  • Specific laboratory focus on DNA vaccines and mechanisms of tumor immune resistance
James Merson, Ph.D.

Chief Virology Officer, Stealth Oncology Company

  • Former SVP and CSO, Vaccine Immunotherapeutics Research Unit, Pfizer
  • Former Global Therapeutic Area Head, Infectious Diseases, Janssen
Patrick Ott, M.D., Ph.D.

Clinical Director, Melanoma Center, Dana Farber Cancer Institute

  • Associate Professor of Medicine, Harvard Medical School
  • Clinical and Translational Investigator, Immunotherapy Trials, Personalized Cancer Vaccines
Menu